3.88

1.27% -0.05

Pre-market: 3.86 -0.02 -0.52%

Aquestive Therapeutics Inc (AQST)

Overview News Price History Option Chain Financials Discussions Forecast

Aquestive Therapeutics Inc stock is traded at $3.88, with a volume of 1.54M. It is down -1.27% in the last 24 hours and down -5.13% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Previous Close:

$3.93

Open:

$3.895

24h Volume:

1.54M

Relative Volume:

0.34

Market Cap:

$473.53M

Revenue:

$44.55M

Net Income/Loss:

$-83.78M

P/E Ratio:

-4.991

EPS:

-0.7774

Net Cash Flow:

$-52.99M

1W Performance:

-5.60%

1M Performance:

-5.13%

6M Performance:

-28.41%

1Y Performance:

+19.38%

1-Day Range:

$3.7664

$3.91

1-Week Range:

$3.7664

$4.17

52-Week Range:

$2.12

$7.55

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name

Aquestive Therapeutics Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

908-941-1900

Address

30 TECHNOLOGY DRIVE, WARREN, NJ

Employee

147

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

AQST's Discussions on Twitter

Compare AQST vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AQST Aquestive Therapeutics Inc	3.88	473.53M	44.55M	-83.78M	-52.99M	-0.7774
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
May-10-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Piper Sandler	Overweight
Mar-28-24	Initiated	Raymond James	Outperform
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy
Aug-20-18	Initiated	JMP Securities	Mkt Outperform
Aug-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

03:04 AM

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

03:04 AM

Mar 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST - ChartMill

Mar 24, 2026

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky - Business Wire

Mar 24, 2026

AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities - GuruFocus

Mar 24, 2026

AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm - Morningstar

Mar 24, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Mar 24, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Mar 24, 2026

Mar 23, 2026

Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar

Mar 23, 2026

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. - GlobeNewswire

Mar 23, 2026

AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 23, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aquestive - GlobeNewswire

Mar 23, 2026

Aquestive Therapeutics appoints Zalewski to chief legal officer and chief compliance officer - ROI-NJ

Mar 23, 2026

AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - Sahm

Mar 23, 2026

Mar 22, 2026

AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 22, 2026

AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill

Mar 22, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to ... - Caledonian Record

Mar 22, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST - GlobeNewswire Inc.

Mar 22, 2026

Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN

Mar 22, 2026

Mar 21, 2026

Published on: 2026-03-22 06:39:45 - baoquankhu1.vn

Mar 21, 2026

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2025 earnings call transcript - MSN

Mar 21, 2026

Aquestive Therapeutics Announces Key Legal Leadership Transition - The Globe and Mail

Mar 21, 2026

Mar 20, 2026

Aquestive names Thomas Zalewski as chief legal officer - Investing.com

Mar 20, 2026

Aquestive Therapeutics Names New Chief Legal, Compliance Officer - Bloomberg Law News

Mar 20, 2026

Aquestive Therapeutics Appoints Thomas A. Zalewski as Chief Legal Officer, Succeeding Lori J. Braender 7 - Minichart

Mar 20, 2026

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 20, 2026

AQST Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire

Mar 20, 2026

Aquestive Therapeutics Appoints Thomas A. Zalewski as Chief Legal & Compliance Officer - citybiz

Mar 20, 2026

Aquestive names Thomas Zalewski as chief legal officer By Investing.com - Investing.com Canada

Mar 20, 2026

Aquestive (NASDAQ: AQST) reshapes legal team with new CLO and equity grants - Stock Titan

Mar 20, 2026

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer - The Manila Times

Mar 20, 2026

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. ... - Caledonian Record

Mar 20, 2026

AQST Stock Price, Quote & Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill

Mar 20, 2026

Mar 19, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph

Mar 19, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive - GlobeNewswire

Mar 19, 2026

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 19, 2026

Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs - MSN

Mar 19, 2026

Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors - GlobeNewswire

Mar 19, 2026